NCT06775327

Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, & Food Effect of Oral INCB000631 to Healthy Adult Participants

A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Dose Escalation, and Food-Effect Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of INCB000631 When Administered Orally to Healthy Adult Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 71 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 19 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study will be conducted to assess the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics, and Food Effect of INCB000631 When Administered Orally to Healthy Adult Participants.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	INCB000631	Oral; Tablet
DRUG	Placebo	Oral; Tablet

Timeline

• Start date: 2025-02-13
• Primary completion: 2025-05-28
• Completion: 2025-05-28
• First posted: 2025-01-15
• Last updated: 2025-06-11

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study